Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioSante Pharmaceuticals to Present at the Rodman & Renshaw

Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Stephen M. Simes, the company's president and chief executive officer, will present a BioSante corporate and clinical overview at the Acumen BioFin Rodman and Renshaw Annual Healthcare Conference, taking place at the New York Palace Hotel in New York City, from November 5 to 7, 2007. Mr. Simes will present on November 5, 2007 at 4:05 p.m. local time.

BioSante Pharmaceuticals to Present at the Rodman & Renshaw

LINCOLNSHIRE, IL | Posted on October 31st, 2007

A live audio webcast of BioSante's presentation may be accessed at http://www.biosantepharma.com/investors/events.html and a replay will be available at the same link for 90 days.

Rodman & Renshaw, a full-service investment bank, is a leading investment banking firm to the biotechnology and pharmaceutical sectors. This conference will feature presentations from over 350 small and medium biotechnology and pharmaceutical companies, to an audience comprised of stock research analysts, institutional money managers, brokers and individual investors, as well as biotechnology and pharmaceutical industry representatives.

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine.

For more information, please click here

Contacts:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316

http://www.mckinneychicago.com

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Little ANTs: Researchers build the world's tiniest engine May 3rd, 2016

Non-animal approach to predict impact of nanomaterials on human lung published Archives of Toxicology publishes workshop recommendations May 2nd, 2016

New drug-delivery approach holds potential for treating obesity May 2nd, 2016

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Announcements

Little ANTs: Researchers build the world's tiniest engine May 3rd, 2016

An Experiment Seeks to Make Quantum Physics Visible to the Naked Eye May 3rd, 2016

Quantum sensors for high-precision magnetometry of superconductors May 3rd, 2016

New drug-delivery approach holds potential for treating obesity May 2nd, 2016

Events/Classes

Non-animal approach to predict impact of nanomaterials on human lung published Archives of Toxicology publishes workshop recommendations May 2nd, 2016

Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016

Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic